This article was originally published back in August, 2019 when we were getting lots of questions about Chris Wood’s teaser pitch — the ad is still largely the same, most of the hints and projections are identical and he still expects that February 2020 approval will send the stock soaring (yes, we’re still getting this […]
Articles
I need to start with this part, the most ludicrous promise made in the ad: “This little-known company, which you can still get in early on today, is at the forefront of this $15.7 trillion economic revolution. “Right now, it does about $3.3 billion in revenue annually… “Next year, I expect it to hit $100 […]
Ray Blanco seems to love pitching a good “results coming soon” story for his FDA Trader ($1,495, no refunds) newsletter over at Agora, and this one is no different from dozens of others he has touted in the past… though the stock is one I haven’t seen him tease before. OK, fine, yes, I know […]
The ads that get the most attention tend to be either those that are most dramatically distributed, with seemingly every single email address getting multiple copies… or those that come with a big promise and a very high price. Today’s topic of interest is the latter, since we’re told that Stansberry Venture Value’s Dave Lashmet […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] It’s a warm Sunday afternoon a few months […]
[Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and more recent comments here.] Picture the gurbling fumaroles of Yellowstone: from the late 1990’s and on into […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. You can see all of his articles archived here. Enjoy!] CoLucid Pharmaceuticals, which recently moved from Durham, NC, to Cambridge, MA, plans an initial public offering. Recent news suggests the […]
[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars! Â You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. His previous columns can be found here. Enjoy!] Every New Year, a friend and I flew to Boston. She’d gone to medical school […]
A Non-Statin Pill That Really Lowers Cholesterol, Blood Pressure and Inflammation without Side Effects Would be a Good Investment, Right?[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Any discussion of cholesterol immediately turns Brobdingnagian, such are the extremes in question. Statins, which lower LDL cholesterol, are bombastically the best-selling drugs of all […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
True, that was back in 2018 -- I covered that one ...
Lashmet was plugging Esperion Therapeutics, Inc. (ESPR) not too long ago, and that has been a real dog....
I have watched ESPR for a while now with mixed assessment. What do the rest of you think? I bought CRSP and Editas, as...
Unfortunate for you if you don't start buying in phases here.....this is a $100 stock in the next 24 mos....
Earlier this year (or maybe it was late last year), I listened to a Stansberry infomercial where Steve Sjuggerud gave hi...
XLNX and ESPR. Let's follow. ESPR's earning will be out shortly....
Blanco's projection for Esperion (ESPR) may have been overblown, but 2020 should be a pivotal year for the company as th...
I can confirm it is ESPR....
The concept that any pre-commercial biotech will cure your retirement woes is ridiculous. That said, as a professional i...
$ESPR > Esperion Announces Completion of Phase 3 LDL-C Lowering Development Program of Bempedoic Acid and Positive Cumul...
The drug from Esperion (Bempedoic Acid) has a number of things going for it: it inhibits cholesterol synthesis at an ear...
I suspect they did that because it’s easier and cheaper to get approval for conditions where current therapies havenâ€...
#Esperion (#ESPR) It seems to me that most people on anti-chlolesteral drugs are fairly healthy. Why would Esperion all...
Since blood pressure and cholesterol-lowering drugs have become cheap and common, heart disease mortality has plummeted,...
I sold my ESPR in early 2015 with a tidy 30% profit. I dodged a bullet as it soon dropped a lot. Didn't repurchase at ...
Esperion to The Medicines Company? Their studies have shown (to date) even better results than approved PSK9 drugs, have...
Too risky for me. Too many deaths in trials. Probably not caused by the drug, as some of the patients were very sick. Wo...
I think you're right, we covered that one here: https://www.stockgumshoe.com/reviews/stansberry-venture/stansberry-ventu...
#ESPR long I just had to say that this comment"You’re either smart and long $ESPR, or you’re a blithering idiot" ma...
$ESPR, no real doubt here, 10% of my overall portfolio is parked in it. Was looking to add another 10%, but the price s...
Psychological obsession often declares its own extinction by the expression of bursts of compulsion in which the obsessi...
$ESPR, long 2x, I think they have 1 Phase 3 readout this quarter, and 3 other Phase 3 readouts by June. As long as they...
$ESPR Credit Suisse’s new analyst, Martin Auster, started coverage of eight biotech stocks with outperform rating, ...
$ESPR full position. I wonder who would buy Esperion? Presumably one of the very big boys, but wouldn’t that suggest a...
4ESPR LONG Esperion initiated with an Outperform at Credit Suisse Credit Suisse analyst Martin Auster started...
$ ESPR LONG Esperion Therapeutics target raised to $88 at UBS reflecting higher peak sales ests for bempedoic aci...
$ESPR LONG theflyonthewall.com: Esperion price target raised to $105 from $70 at Stifel Stifel analyst Alex Sch...
$ESPR -Me too: twice with statin-caused musculature problems - first time after many years on Lipitor; two years off, th...
Fred, From past KSS discussions, it is a given that $ESPR is unique and should be profitable and bound for success. Th...
#ESPR LONG From J.P. Morgan Nuetral disclosures. J.P. Morgan does and seeks to do business with companies cover...
Bempedoic Acid: A Statin Equivalent for the Statin Intolerant $ESPR The statin class provided a major breakthrough f...
$ESPR ++ Acute Coronary Syndrome Market in 2017 and Beyond 0 Shares Acute coronary syndrome (ACS) refers to a sp...